Related Experiment Video
Updated: Jun 16, 2026

Direct Mouse Trauma/Burn Model of Heterotopic Ossification
Published on: August 6, 2015
Repurposed Drugs for Heterotopic Ossification Management: Revitalizing Therapeutic Strategies.
Ana Alonso-Pérez1, Eloi Franco-Trepat1, María Guillán-Fresco1
1Musculoskeletal Pathology Group, Laboratory 18, Health Research Institute of Santiago de Compostela (IDIS), Santiago University Clinical Hospital SERGAS, 15706 Santiago de Compostela, Spain.
A novel drug combination (tritherapy) effectively promotes adipogenesis while inhibiting osteoblastogenesis and abnormal bone growth. This therapeutic approach shows promise for treating heterotopic ossification (HO) and other bone disorders.
Area of Science:
- Biomedical Science
- Cell Biology
- Pharmacology
Background:
- Heterotopic ossification (HO) is abnormal bone growth in soft tissues, lacking effective treatments.
- Osteoblastogenesis and adipogenesis are opposing cellular processes, offering a therapeutic target.
- Existing HO treatments have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify a repurposed drug combination for inhibiting osteoblastogenesis by promoting adipogenesis.
- To evaluate the anti-osteoblastogenic and pro-adipogenic effects of tritherapy.
- To assess the clinical potential of tritherapy in treating HO.
Main Methods:
- Docking experiments identified potential drug candidates targeting peroxisome proliferator-activated receptor-γ.
- In vitro studies used mesenchymal stem cells, osteoblast-like cells, and chondrocytes to assess drug effects.
- Gene expression analysis (RT-qPCR) and clinical treatment of a congenital HO patient were performed.
Main Results:
- Tritherapy synergistically increased adipogenic markers and decreased osteoblastogenic markers in vitro.
- The drug combination reduced ossification markers in an endochondral ossification model.
- Tritherapy promoted bone resorption in a patient with progressive osseous heteroplasia.
Conclusions:
- Tritherapy effectively induces adipogenesis, inhibits osteoblastogenesis, and suppresses endochondral ossification.
- The findings suggest tritherapy as a potential therapeutic tool for preventing abnormal bone growth.
- Clinical observations in a congenital HO patient support the therapeutic potential of tritherapy for HO treatment.
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Poisoning: Treatment Strategies
Rheumatic Heart Disease III: Medical Management

